IMTX · NASDAQ · Biotechnology

Immatics

Develops PRAME-focused cancer therapies with cell therapy and TCR bispecific programs.

$9.35
After-hours close−0.09 (−0.95%)
At close$9.44(+0.85%)
DateEstimateReportedSurprise
Nov 2026−$0.58
Aug 2026−$0.43
Aug 2026−$0.48−$0.53−10.5%
May 2026−$0.42−$0.50−19.0%
Mar 2026−$0.48−$0.34+29.2%
Nov 2025−$0.44−$0.49−11.5%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
Jun 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Dec 2019
Jun 2019
Mar 2019
Dec 2018
Sep 2018
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 17, 2026−$0.58$12.7M
Aug 19, 2026−$0.43$11.9M
Aug 18, 2026−$0.48−$0.53−10.5%$11.9M$11.9M−0.2%
May 12, 2026−$0.42−$0.50−19.0%$9.8M$8.8M−10.3%
Mar 5, 2026−$0.48−$0.34+29.2%$11.3M$22.3M+98.2%
Nov 17, 2025−$0.44−$0.49−11.5%$10.7M$6.1M−43.3%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 13, 2025
Mar 27, 2025
Nov 18, 2024
Aug 13, 2024
May 14, 2024
Mar 21, 2024
Nov 14, 2023
Aug 17, 2023
May 16, 2023
Mar 21, 2023
Nov 17, 2022
Aug 9, 2022
Jun 2, 2022
Mar 23, 2022
Nov 16, 2021
Aug 10, 2021
May 18, 2021
Mar 30, 2021
Dec 2, 2020
Sep 3, 2020
Jun 8, 2020
Mar 6, 2020
Dec 31, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018